Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Cancer Res. 2016 Aug 16;76(19):5671–5682. doi: 10.1158/0008-5472.CAN-16-0144

Figure 6. Ly-6C+ monocytic MDSCs require CCR2 for accumulation in glioma.

Figure 6

(A) Schematic of mixed-bone marrow chimera experiments using wild-type CD45.1+ and CD45.2+ Ccr2RFP/RFP (CCR2-deficient) marrow. (B) Wild-type CD45.1+ or CCR2-deficient CD45.2+ glioma-infiltrating MDSC subsets in brain tumor-bearing chimeric mice (n = 7). Data are representative of at least 2 independent experiments. Data are represented as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by Student’s t test.